Pharma Pulse 12/23/24: Impact of DEA Telehealth Extensions, Big Jump in US Healthcare Spending & more

The Impact of DEA Telehealth Extensions on Patient Access

In this part of his Pharmaceutical Executive video interview, Peter Ax, CEO of UpScriptHealth, discusses the recent DEA extensions of telehealth for controlled substances and new treatment modalities or patient populations he anticipates will become more accessible through telehealth in 2025.

Hospital, Prescription Drug Spending Fuel Big Jump in U.S. Healthcare Spending

Spending reached $4.86 trillion in 2023, a 7.5% increase from 2022 The growth in spending on hospital care was the highest since 1990.

Lilly Cements Weight Loss Lead After Novo Trial Setback

The fierce battle between weight-loss drug makers has led to sky-high Wall Street expectations, with investors anticipating new medicines that are incrementally more powerful and easier to take.

U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen

Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test.i The indication was approved based on a statistically significant and clinically meaningful improvement in response rate and durability of response in treatment-naïve patients treated with BRAFTOVI in combination with cetuximab and mFOLFOX6 from the Phase III BREAKWATER trial. Continued approval for this indication is contingent upon verification of clinical benefit. This accelerated approval is among the first in the industry to be conducted under the FDA’s Project FrontRunner, which seeks to support the development and approval of new cancer drugs for advanced or metastatic disease.

Nicholas Saraceno on LinkedIn

Volume II of Pharmaceutical Commerce Magazine's "Supply Chain Solutions" has now gone live. I encourage you all to give it a quick read for a look at the latest happenings within the industry, including the examination of post-launch price developments in the United States and Europe, Novo Nordisk making waves, and much more.
https://lnkd.in/dhrp2CaU

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs